Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aAPC-NK002
- Development stage
- Preclinical
- Lead developer
- Shanghai YaKe Biotechnology
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
aAPC-NK002 is a preclinical-stage artificial antigen-presenting cell (aAPC) technology developed by YaKe Biotechnology for the ex vivo expansion and activation of natural killer (NK) cells. The platform is designed to enhance the cytotoxic activity of NK cells against cancer cells. In vitro studies have demonstrated that NK cells expanded using the aAPC-NK002 system exhibit potent tumor-killing activity against A549 lung cancer cells. The technology is being developed for applications in cancer prevention, immune enhancement, and oncology.
02
Targets
TNFRSF9 (CD137 extracellular domain)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL21R (Interleukin-21 receptor)NKG2D (Natural killer group 2 member D receptor)
Beyond the preview
Go deeper on aAPC-NK002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aAPC-NK002.